The stock market cares more about future earnings potential than the past -- and that may be why Nvidia, Microsoft, Apple (NASDAQ: AAPL), and Amazon (NASDAQ: AMZN) are all worth more than Alphabet ...

Is Alphabet stock a sell? It's less clear why investors have so quickly abandoned their optimism about the DST repeal, however, and have turned to selling Alphabet stock. Valuation might be a concern.

Is Alphabet stock a sell? It's less clear why investors have so quickly abandoned their optimism about the DST repeal, however, and have turned to selling Alphabet stock. Valuation might be a concern.

That's good news for Google parent Alphabet, and explains why the stock popped early today. Is Alphabet stock a sell?

Alphabet's revenue and earnings growth are near the top compared to other "Magnificent Seven" stocks. Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) has been one of the most hated big tech stocks in the ...

Financial giants have made a conspicuous bearish move on Alphabet. Our analysis of options history for Alphabet GOOGL revealed 20 unusual trades. Delving into the details, we found 25% of traders ...

Alphabet gains regulatory support for AI in search, with Gemini set to boost engagement and revenue amid manageable legal risks. See why GOOG stock is a strong buy.

Perhaps the simplest reason why Tesla, Apple, and Alphabet are underperforming their Magnificent Seven peers is that they are on the unfavorable side of this great divide.

Squali anticipates continued growth across Alphabet’s business units, which include search. This is despite investor concerns over Alphabet’s search future as new artificial intelligence tools ...

To me, the deal with OpenAI is a transformative game changer for Alphabet in the long run and I see the stock as a no-brainer buy right now. Should you invest $1,000 in Alphabet right now?

It's why Alphabet Inc. has been a highly contested stock among investors trying to grapple with how to value its business at a time when it could face disruption from artificial intelligence.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.